logo-loader
viewNanoveu Ltd

Nanoveu shares surge as antiviral technology independently validated against human coronaviruses

In just 30 minutes the number of viable or infectious coronavirus particles was reduced by 99.99%.

Nanoveu Ltd - Nanoveu antiviral technology independently validated against human Coronaviruses
Nanoveu has developed antiviral screen and cover prototypes

Nanoveu Ltd (ASX:NVU) has more than doubled on receiving further successful independent testing of its antiviral technology against the human transmitted coronavirus strain OC43 by Bioscience Laboratories, at its testing facility in Montana, USA.

Testing involved placing a solution containing OC43 strain coronaviruses on a thin film containing the antiviral technology.

The company's antiviral protectors protect smartphone and tablet users from viruses and bacteria.

Betacoronavirus targeted

In line with Nanoveu’s testing of the MHV-A59 strain, which demonstrated 90% elimination of the virus in just 10 minutes, this recent research on the OC43 strain has targeted a betacoronavirus, which are single-stranded RNA viruses emerging from animals and are typically associated with respiratory ailments.

SARS, MERS, and COVID-19 are all forms of betacoronavirus.

Shares have been as much as 106% higher to 17.5 cents intra-day and are well up from 2.5 cents at close on April 2.

“Strong validation”

Nanoveu executive chairman and CEO Alfred Chong said: “Nanoveu has again received a strong validation from further independent testing of its antiviral technology, which has all but eradicated the coronavirus in half an hour.

“It is particularly pleasing to see that the antiviral technology is not only proven as an effective agent at killing certain strands of coronaviruses but is highly successful at killing viruses capable of infecting humans.

“Given the strong public health focus on COVID-19, these test results represent fantastic news for Nanoveu as well as to the broader population and I am proud to say we are another step closer to providing safer devices for all digital screen users.”

TGA submission

With the completion of the Bioscience Labs testing, Nanoveu now possesses multiple independent research results demonstrating the effectiveness of its antiviral technology against pathogenic betacoronaviruses affecting animals, as well as humans.

These test results will assist Nanoveu in its upcoming submission to the Australian Therapeutic Goods Administration (TGA) as a Class I Medical Device.

Class I Medical Device status is given to low-risk and non-invasive medical equipment, such as surgical retractors and has a two-day approval period.

The product certification is an important step permitting Nanoveu’s antiviral protectors to be sold to Australian consumers.

Looking forward

The company has commenced an application with the Environmental Protection Agency (EPA) in the United States to enable its antiviral products to be sold in the US, with approval expected to take nine weeks.

Nanoveu's commercialisation guidance is now targeting product availability in late quarter two or early quarter three of 2020.

Quick facts: Nanoveu Ltd

Price: 0.075 AUD

ASX:NVU
Market: ASX
Market Cap: $9.94 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Nanoveu Ltd named herein, including the promotion by the Company of Nanoveu Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Nanoveu Ltd looking to have its antiviral smartphone protectors on sale...

Nanoveu Ltd’s (ASX:NVU) chairman and chief executive Alfred Chong discusses with Proactive's Andrew Scott their antiviral protective screens and cases for tablets and smartphones. He says the nanotechnology incorporated within them has proven to be effective against viruses and bacteria such...

on 21/4/20

2 min read